Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
A clinical-stage biotech company developing precision oncology therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for Hard-to-Treat cancers: first human trial of ERAS-0015 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: ERAS-4001 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and find the best dose, either alone or with other treatments. About 200 adults who have no good standard op…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC